TScan Therapeutics strengthens heme pipeline with dual IND clearances

TScan Therapeutics advances its ALLOHA trial and expands CD45-targeted TCR-T coverage. Discover what this means for relapse prevention.

TScan Therapeutics advances its ALLOHA trial and expands CD45-targeted TCR-T coverage. Discover what this means for relapse prevention.